A Simplified Understanding of the Black Swan: Anti-phospholipid Antibody Syndrome
Open Access
- 30 April 2019
- journal article
- review article
- Published by Journal of Nepal Medical Association (JNMA) in Journal of Nepal Medical Association
- Vol. 57 (216), 133-143
- https://doi.org/10.31729/jnma.4226
Abstract
Anti-phospholipid antibody syndrome is caused by the presence of specific antibodies against phospholipid-binding plasma proteins in serum of patient, with or without underlying autoimmune diseases, that causes prolongation of tests of coagulation. High index of clinical suspicion is required for diagnosis. Stroke or myocardial infarction in young, unprovoked recurrent deep vein thrombosis and recurrent pregnancy loss are typical scenarios where it should be suspected. Presence of non-criteria manifestations like livedoreticularis, skin ulcers, nephropathy, valvular-heart disease and thrombocytopenia adds to diagnostic clue for presence of the syndrome. Therapeutic anti-coagulation with heparin followed by warfarin is required for patients with acute thrombosis. Those with venous thrombosis are given moderate-intensity warfarin(INR 2-3), whereas those with arterial thrombosis or recurrent venous thrombosis even on warfarin are treated with high intensity warfarin (INR 3-4). Similarly, anticoagulation with heparin is advised throughout pregnancy and up to six weeks postpartum. Treatment recommendations are still not clear for asymptomatic patients and in those with non-criteria manifestations of the disease. Steroids, intravenous immunoglobulin and immunosuppressant are reported to be effective in catastrophic cases characterized by rapid small vessel thrombotic involvement of multiple organ systems. Studies are evaluating the efficacy of direct thrombin inhibitors in the management of refractory cases.Keywords
This publication has 62 references indexed in Scilit:
- Eculizumab Improves Posttransplant Thrombotic Microangiopathy Due to Antiphospholipid Syndrome Recurrence but Fails to Prevent Chronic Vascular ChangesAmerican Journal of Transplantation, 2013
- Laboratory diagnosis of the antiphospholipid syndrome: a plethora of obstacles to overcomeEuropean Journal of Haematology, 2009
- Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodiesArthritis Care & Research, 2008
- Hydroxychloroquine directly reduces the binding of antiphospholipid antibody–β2-glycoprotein I complexes to phospholipid bilayersBlood, 2008
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidityThrombosis and Haemostasis, 2006
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999
- Increased thromboxane formation in patients with antiphospholipid syndromeEuropean Journal of Clinical Investigation, 1990
- SYNDROME OF THE BLACK SWANRheumatology, 1987
- The natural history of systemic lupus erythematosus: An approach to its study through chronic biologic false positive reactorsJournal of Chronic Diseases, 1955